|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007137,
umls-concept:C0011243,
umls-concept:C0031437,
umls-concept:C0086418,
umls-concept:C0460004,
umls-concept:C0683598,
umls-concept:C1135135,
umls-concept:C1443775,
umls-concept:C1521761,
umls-concept:C1523298,
umls-concept:C1548328,
umls-concept:C1553412,
umls-concept:C2587213,
umls-concept:C2752241
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-1-16
|
|
pubmed:abstractText |
Although the epidermal growth factor receptor (EGFR) is overexpressed in a majority of head and neck squamous cell carcinomas (HNSCC), only a minority of patients derive substantial clinical benefit from EGFR inhibitors. We initiated the present study to identify the mechanisms underlying erlotinib resistance in a panel of HNSCC cell lines. Methods: We used [(3)H]thymidine incorporation to characterize the heterogeneity of responsiveness to erlotinib-mediated growth inhibition in a panel of 27 human HNSCC cells. We characterized the molecular mechanisms involved in resistance using a representative subset of six erlotinib-sensitive and erlotinib-resistant HNSCC lines.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-11706397,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-12163402,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-12599217,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-14706341,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-15057284,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-15674322,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-16361555,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-16424029,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-16585207,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-16763280,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-16763281,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-16857825,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-16912200,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-17211382,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-17211407,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-17237287,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-17269160,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-17508028,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-17541031,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-17609492,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-17804704,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-17909010,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-17962618,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-18281673,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-18316572,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-18376396,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-18381893,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-18483486,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-8912870,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19147758-9233779
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cadherins,
http://linkedlifedata.com/resource/pubmed/chemical/Homeodomain Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Transcription Factors,
http://linkedlifedata.com/resource/pubmed/chemical/ZEB1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/delta-Crystallins,
http://linkedlifedata.com/resource/pubmed/chemical/erlotinib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
532-42
|
|
pubmed:dateRevised |
2011-9-26
|
|
pubmed:meshHeading |
pubmed-meshheading:19147758-Cadherins,
pubmed-meshheading:19147758-Carcinoma, Squamous Cell,
pubmed-meshheading:19147758-Cell Line, Tumor,
pubmed-meshheading:19147758-Drug Resistance, Neoplasm,
pubmed-meshheading:19147758-Epithelium,
pubmed-meshheading:19147758-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:19147758-Head and Neck Neoplasms,
pubmed-meshheading:19147758-Homeodomain Proteins,
pubmed-meshheading:19147758-Humans,
pubmed-meshheading:19147758-Mesoderm,
pubmed-meshheading:19147758-Phenotype,
pubmed-meshheading:19147758-Protein Kinase Inhibitors,
pubmed-meshheading:19147758-Quinazolines,
pubmed-meshheading:19147758-Receptor, Epidermal Growth Factor,
pubmed-meshheading:19147758-Transcription Factors,
pubmed-meshheading:19147758-delta-Crystallins
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines.
|
|
pubmed:affiliation |
Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
|
|
pubmed:publicationType |
Journal Article
|
